In order to reduce possible resistance to SHIPi, pan-SHIP1/2 inhibitors could also be combined with traditional chemotherapies to improve their cytotoxicity on cancer cells or chemotherapy could be followed by SHIP1 selective inhibitors, as immunotherapeutics, for an improved response to the tumor. Here, INPP5D is linked to cancer.